Coleman Mark 4

What Happened Mark Coleman, a director of Axsome Therapeutics (AXSM), sold 25,000 shares on Feb 26, 2026, in an open‑market disposition for a total of $4,027,750 (weighted average price $161.11). The sales represent the disposition of shares underlying previously exercised stock options and were executed pursuant to a pre‑approved 10b5‑1 plan that has now been completed. The reported sale prices ranged between $160.33 and $162.26.

Key Details

• Transaction date: 2026-02-26 (Form 4 filed 2026-02-27; filing appears timely).
• Transaction type/code: Sale (S) — underlying shares from previously exercised options (footnote F1).
• Shares sold: 25,000; Weighted average sale price: $161.11; Total proceeds: $4,027,750.
• Price range for series of trades: $160.33 – $162.26 (footnote F3).
• Executed under a pre‑approved 10b5‑1 plan, which has been completed (footnote F2).
• Indirect ownership note: some shares are held by an entity for which Coleman has voting and dispositive power, making him an indirect beneficial owner (footnote F4).
• Shares owned after transaction: Not specified in the provided excerpt.

Context This was a sale of shares that had already been acquired via option exercise (i.e., the shares sold were not newly exercised in the same reported transaction). Trades executed under a 10b5‑1 plan are pre‑arranged and are generally treated as routine dispositions rather than ad‑hoc trading; the filing does not provide evidence of intent or sentiment beyond the registered sale.